• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Abbott launches Amplatzer Talisman occlusion system in Europe

Abbott launches Amplatzer Talisman occlusion system in Europe

September 7, 2022 By Sean Whooley

Abbott amplatzer talisman pfo occluder
[Image from Abbott]
Abbott (NYSE:ABT) announced today that it launched its Amplatzer Talisman patent foramen ovale (PFO) occlusion system in Europe.

PFO is a hole in the heart that doesn’t close following birth. The company designed the Amplatzer Talisman to treat people with PFO who experienced a stroke and are at risk of having another.

Occlusion with the Talisman PFO is a minimally invasive, catheter-based procedure. It seals off the opening to reduce the risk of another stroke.

Abbott Park, Illinois-based Abbott’s new Talisman PFO occluders come pre-attached to the delivery cable. This design reduces preparation time for doctors and increases ease of use.

Manchester England-based cardiologist Matthew Daniels completed the first European procedure with Talisman PFO.

“Guidelines from industry organizations and clinical trial data continue to reinforce the benefits of PFO closure for people who have had a PFO-associated stroke,” Daniels said in a news release. “We’re excited that physicians around Europe now have access to the Talisman device to help reduce patients’ risk and worry of experiencing another stroke.”

Abbott’s Amplatzer Talisman builds off the company’s Amplatzer PFO occluder system. Previously, physicians had to attach it to the delivery cable before implant. However, the Talisman comes pre-assembled with the Amplatzer Trevisio delivery cable.

Talisman also accommodates a range of patient anatomies. It features a 30mm occluder size to optimize fit in the heart. It is also fully recapturable and repositionable for easy adjustments and accurate placement.

“Our trusted PFO closure technology has been used to treat more than 180,000 people worldwide and we haven’t let up on continuing to innovate to best serve physicians and patients,” Michael Dale, SVP of Abbott’s structural heart business, said in the news release. “The Talisman system simplifies the procedure for doctors and helps patients quickly get back to living fuller, healthier lives.”

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Featured, Implants, Structural Heart Tagged With: Abbott

More recent news

  • Paradromics’ first study participant uses BCI for real-time speech
  • Medtronic hires former Recor CEO to run interventional cardiology group
  • Abbott wins FDA approval for Aveir VR Mini ventricular leadless pacemaker
  • Dexcom CFO to expand into COO role
  • Powerful Medical announces FDA De Novo nod for AI ECG and other extra medtech news

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy